Therapeutic effects of recombinant Salmonella typhimurium harboring CCL22 miRNA on atopic dermatitis-like skin in mice

Won Suck Yoon, Seung Seok Lee, Yang Seok Chae, Yong Keun Park

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Th-2-biased immune responses are known to play a key role in the pathogenesis of atopic dermatitis. In particular, the macrophage-derived chemokine CCL22 is directly implicated in Th-2-associated skin inflammatory reactions, and its levels are significantly elevated in serum and are correlated with disease severity in atopic dermatitis. In this study, we tested the development of genetic therapeutic options to treat atopic dermatitis using bacteria expressing miRNA. We constructed a recombinant strain of Salmonella typhimurium expressing CCL22 miRNA (ST-miRCCL22) for the in vivo knockdown of CCL22. The CCL22 gene was downregulated with CCL22 miRNA in activated lymphocytes. In mice with a cutaneous disease similar to atopic dermatitis, interleukin-4 was inhibited and interferon- γ was induced after treatments with ST-miRCCL22. Furthermore, CCL22 levels were suppressed in the atopic mice treated with ST-miRCCL22. These results suggest that ST-miRCCL22 may be an effective genetic agent for treating atopic dermatitis.

Original languageEnglish
Pages (from-to)63-70
Number of pages8
JournalExperimental and Molecular Medicine
Volume43
Issue number2
DOIs
Publication statusPublished - 2011 Feb 1

Fingerprint

Salmonella
Therapeutic Uses
Atopic Dermatitis
Salmonella typhimurium
MicroRNAs
Skin
Chemokine CCL22
Lymphocytes
Skin Diseases
Interleukin-4
Interferons
Bacteria
Down-Regulation
Genes
Serum

Keywords

  • Atopic
  • Biological therapy
  • Chemokine CCL22
  • Dermatitis
  • Immunotherapy
  • RNA interference
  • Salmonella typhimurium

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Therapeutic effects of recombinant Salmonella typhimurium harboring CCL22 miRNA on atopic dermatitis-like skin in mice. / Yoon, Won Suck; Lee, Seung Seok; Chae, Yang Seok; Park, Yong Keun.

In: Experimental and Molecular Medicine, Vol. 43, No. 2, 01.02.2011, p. 63-70.

Research output: Contribution to journalArticle

@article{6c85d7eb54d547e8baf5f96d576b5153,
title = "Therapeutic effects of recombinant Salmonella typhimurium harboring CCL22 miRNA on atopic dermatitis-like skin in mice",
abstract = "Th-2-biased immune responses are known to play a key role in the pathogenesis of atopic dermatitis. In particular, the macrophage-derived chemokine CCL22 is directly implicated in Th-2-associated skin inflammatory reactions, and its levels are significantly elevated in serum and are correlated with disease severity in atopic dermatitis. In this study, we tested the development of genetic therapeutic options to treat atopic dermatitis using bacteria expressing miRNA. We constructed a recombinant strain of Salmonella typhimurium expressing CCL22 miRNA (ST-miRCCL22) for the in vivo knockdown of CCL22. The CCL22 gene was downregulated with CCL22 miRNA in activated lymphocytes. In mice with a cutaneous disease similar to atopic dermatitis, interleukin-4 was inhibited and interferon- γ was induced after treatments with ST-miRCCL22. Furthermore, CCL22 levels were suppressed in the atopic mice treated with ST-miRCCL22. These results suggest that ST-miRCCL22 may be an effective genetic agent for treating atopic dermatitis.",
keywords = "Atopic, Biological therapy, Chemokine CCL22, Dermatitis, Immunotherapy, RNA interference, Salmonella typhimurium",
author = "Yoon, {Won Suck} and Lee, {Seung Seok} and Chae, {Yang Seok} and Park, {Yong Keun}",
year = "2011",
month = "2",
day = "1",
doi = "10.3858/emm.2011.43.2.008",
language = "English",
volume = "43",
pages = "63--70",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "2",

}

TY - JOUR

T1 - Therapeutic effects of recombinant Salmonella typhimurium harboring CCL22 miRNA on atopic dermatitis-like skin in mice

AU - Yoon, Won Suck

AU - Lee, Seung Seok

AU - Chae, Yang Seok

AU - Park, Yong Keun

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Th-2-biased immune responses are known to play a key role in the pathogenesis of atopic dermatitis. In particular, the macrophage-derived chemokine CCL22 is directly implicated in Th-2-associated skin inflammatory reactions, and its levels are significantly elevated in serum and are correlated with disease severity in atopic dermatitis. In this study, we tested the development of genetic therapeutic options to treat atopic dermatitis using bacteria expressing miRNA. We constructed a recombinant strain of Salmonella typhimurium expressing CCL22 miRNA (ST-miRCCL22) for the in vivo knockdown of CCL22. The CCL22 gene was downregulated with CCL22 miRNA in activated lymphocytes. In mice with a cutaneous disease similar to atopic dermatitis, interleukin-4 was inhibited and interferon- γ was induced after treatments with ST-miRCCL22. Furthermore, CCL22 levels were suppressed in the atopic mice treated with ST-miRCCL22. These results suggest that ST-miRCCL22 may be an effective genetic agent for treating atopic dermatitis.

AB - Th-2-biased immune responses are known to play a key role in the pathogenesis of atopic dermatitis. In particular, the macrophage-derived chemokine CCL22 is directly implicated in Th-2-associated skin inflammatory reactions, and its levels are significantly elevated in serum and are correlated with disease severity in atopic dermatitis. In this study, we tested the development of genetic therapeutic options to treat atopic dermatitis using bacteria expressing miRNA. We constructed a recombinant strain of Salmonella typhimurium expressing CCL22 miRNA (ST-miRCCL22) for the in vivo knockdown of CCL22. The CCL22 gene was downregulated with CCL22 miRNA in activated lymphocytes. In mice with a cutaneous disease similar to atopic dermatitis, interleukin-4 was inhibited and interferon- γ was induced after treatments with ST-miRCCL22. Furthermore, CCL22 levels were suppressed in the atopic mice treated with ST-miRCCL22. These results suggest that ST-miRCCL22 may be an effective genetic agent for treating atopic dermatitis.

KW - Atopic

KW - Biological therapy

KW - Chemokine CCL22

KW - Dermatitis

KW - Immunotherapy

KW - RNA interference

KW - Salmonella typhimurium

UR - http://www.scopus.com/inward/record.url?scp=79952419619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952419619&partnerID=8YFLogxK

U2 - 10.3858/emm.2011.43.2.008

DO - 10.3858/emm.2011.43.2.008

M3 - Article

VL - 43

SP - 63

EP - 70

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 2

ER -